Click on headlines below to download research

Near-term goals in sight with FY23 momentum
AFT Pharmaceuticals | 24/05/2023

AFT Pharmaceuticals reported another strong fiscal year, capping off three consecutive years of double-digit top-line growth. FY23 revenues of NZ$156.6m…

Maxigesic IV closer to FDA approval
AFT Pharmaceuticals | 02/05/2023

AFT Pharmaceuticals has announced that the US FDA has allocated a Prescription Drug User Fee Act (PDUFA) date for Maxigesic IV, an intravenous form of…

Maxigesic international momentum continues
AFT Pharmaceuticals | 28/03/2023

AFT Pharmaceuticals (AFT) has announced that it has signed three additional licensing agreements for Maxigesic IV – with Labatec in Switzerland and…